DsrA-deficient mutant of Haemophilus ducreyi is impaired in its ability to infect human volunteers

C. T H Bong, R. E. Throm, K. R. Fortney, Barry Katz, A. F. Hood, C. Elkins, Stanley Spinola

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Haemophilus ducreyi produces an outer membrane protein called DsrA, which is required for serum resistance. An isogenic dsrA mutant, FX517, was constructed previously in H. ducreyi 35000. Compared to its parent, FX517 cannot survive in normal human serum. When complemented in trans with a plasmid containing dsrA, FX517 is converted to a serum-resistant phenotype (C. Elkins, K. J. Morrow, Jr., and B. Olsen. Infect. Immun. 68:1608-1619, 2000). To test whether dsrA was transcribed in vivo, we successfully amplified transcripts in five biopsies obtained from four experimentally infected human subjects. To test whether DsrA was required for virulence, six volunteers were experimentally infected with 35000 and FX517 and observed for papule and pustule formation. Each subject was inoculated with two doses (70 to 80 CFU) of live 35000 and 1 dose of heat-killed bacteria on one arm and with three doses (ranging from 35 to 800 CFU) of live FX517 on the other arm. Papules developed at similar rates at sites inoculated with the mutant or parent. However, mutant papule surface areas were significantly smaller than parent papules. The pustule formation rate was 58% (95% confidence interval [CI] of 28 to 85%) at 12 parent sites, and 0% (95% CI of 0 to 15%) at 18 mutant sites (P = 0.0004). Although biosafety regulations precluded our testing the complemented mutant in humans, these results suggest that expression of DsrA facilitates the ability of H. ducreyi to progress to the pustular stage of disease.

Original languageEnglish
Pages (from-to)1488-1491
Number of pages4
JournalInfection and Immunity
Volume69
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Haemophilus ducreyi
Volunteers
Serum
Confidence Intervals
Virulence
Membrane Proteins
Plasmids
Hot Temperature
Bacteria
Phenotype
Biopsy

ASJC Scopus subject areas

  • Immunology

Cite this

DsrA-deficient mutant of Haemophilus ducreyi is impaired in its ability to infect human volunteers. / Bong, C. T H; Throm, R. E.; Fortney, K. R.; Katz, Barry; Hood, A. F.; Elkins, C.; Spinola, Stanley.

In: Infection and Immunity, Vol. 69, No. 3, 2001, p. 1488-1491.

Research output: Contribution to journalArticle

Bong, C. T H ; Throm, R. E. ; Fortney, K. R. ; Katz, Barry ; Hood, A. F. ; Elkins, C. ; Spinola, Stanley. / DsrA-deficient mutant of Haemophilus ducreyi is impaired in its ability to infect human volunteers. In: Infection and Immunity. 2001 ; Vol. 69, No. 3. pp. 1488-1491.
@article{825a5859b64d4493843a4fde405bb33f,
title = "DsrA-deficient mutant of Haemophilus ducreyi is impaired in its ability to infect human volunteers",
abstract = "Haemophilus ducreyi produces an outer membrane protein called DsrA, which is required for serum resistance. An isogenic dsrA mutant, FX517, was constructed previously in H. ducreyi 35000. Compared to its parent, FX517 cannot survive in normal human serum. When complemented in trans with a plasmid containing dsrA, FX517 is converted to a serum-resistant phenotype (C. Elkins, K. J. Morrow, Jr., and B. Olsen. Infect. Immun. 68:1608-1619, 2000). To test whether dsrA was transcribed in vivo, we successfully amplified transcripts in five biopsies obtained from four experimentally infected human subjects. To test whether DsrA was required for virulence, six volunteers were experimentally infected with 35000 and FX517 and observed for papule and pustule formation. Each subject was inoculated with two doses (70 to 80 CFU) of live 35000 and 1 dose of heat-killed bacteria on one arm and with three doses (ranging from 35 to 800 CFU) of live FX517 on the other arm. Papules developed at similar rates at sites inoculated with the mutant or parent. However, mutant papule surface areas were significantly smaller than parent papules. The pustule formation rate was 58{\%} (95{\%} confidence interval [CI] of 28 to 85{\%}) at 12 parent sites, and 0{\%} (95{\%} CI of 0 to 15{\%}) at 18 mutant sites (P = 0.0004). Although biosafety regulations precluded our testing the complemented mutant in humans, these results suggest that expression of DsrA facilitates the ability of H. ducreyi to progress to the pustular stage of disease.",
author = "Bong, {C. T H} and Throm, {R. E.} and Fortney, {K. R.} and Barry Katz and Hood, {A. F.} and C. Elkins and Stanley Spinola",
year = "2001",
doi = "10.1128/IAI.69.3.1488-1491.2001",
language = "English",
volume = "69",
pages = "1488--1491",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - DsrA-deficient mutant of Haemophilus ducreyi is impaired in its ability to infect human volunteers

AU - Bong, C. T H

AU - Throm, R. E.

AU - Fortney, K. R.

AU - Katz, Barry

AU - Hood, A. F.

AU - Elkins, C.

AU - Spinola, Stanley

PY - 2001

Y1 - 2001

N2 - Haemophilus ducreyi produces an outer membrane protein called DsrA, which is required for serum resistance. An isogenic dsrA mutant, FX517, was constructed previously in H. ducreyi 35000. Compared to its parent, FX517 cannot survive in normal human serum. When complemented in trans with a plasmid containing dsrA, FX517 is converted to a serum-resistant phenotype (C. Elkins, K. J. Morrow, Jr., and B. Olsen. Infect. Immun. 68:1608-1619, 2000). To test whether dsrA was transcribed in vivo, we successfully amplified transcripts in five biopsies obtained from four experimentally infected human subjects. To test whether DsrA was required for virulence, six volunteers were experimentally infected with 35000 and FX517 and observed for papule and pustule formation. Each subject was inoculated with two doses (70 to 80 CFU) of live 35000 and 1 dose of heat-killed bacteria on one arm and with three doses (ranging from 35 to 800 CFU) of live FX517 on the other arm. Papules developed at similar rates at sites inoculated with the mutant or parent. However, mutant papule surface areas were significantly smaller than parent papules. The pustule formation rate was 58% (95% confidence interval [CI] of 28 to 85%) at 12 parent sites, and 0% (95% CI of 0 to 15%) at 18 mutant sites (P = 0.0004). Although biosafety regulations precluded our testing the complemented mutant in humans, these results suggest that expression of DsrA facilitates the ability of H. ducreyi to progress to the pustular stage of disease.

AB - Haemophilus ducreyi produces an outer membrane protein called DsrA, which is required for serum resistance. An isogenic dsrA mutant, FX517, was constructed previously in H. ducreyi 35000. Compared to its parent, FX517 cannot survive in normal human serum. When complemented in trans with a plasmid containing dsrA, FX517 is converted to a serum-resistant phenotype (C. Elkins, K. J. Morrow, Jr., and B. Olsen. Infect. Immun. 68:1608-1619, 2000). To test whether dsrA was transcribed in vivo, we successfully amplified transcripts in five biopsies obtained from four experimentally infected human subjects. To test whether DsrA was required for virulence, six volunteers were experimentally infected with 35000 and FX517 and observed for papule and pustule formation. Each subject was inoculated with two doses (70 to 80 CFU) of live 35000 and 1 dose of heat-killed bacteria on one arm and with three doses (ranging from 35 to 800 CFU) of live FX517 on the other arm. Papules developed at similar rates at sites inoculated with the mutant or parent. However, mutant papule surface areas were significantly smaller than parent papules. The pustule formation rate was 58% (95% confidence interval [CI] of 28 to 85%) at 12 parent sites, and 0% (95% CI of 0 to 15%) at 18 mutant sites (P = 0.0004). Although biosafety regulations precluded our testing the complemented mutant in humans, these results suggest that expression of DsrA facilitates the ability of H. ducreyi to progress to the pustular stage of disease.

UR - http://www.scopus.com/inward/record.url?scp=0035119494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035119494&partnerID=8YFLogxK

U2 - 10.1128/IAI.69.3.1488-1491.2001

DO - 10.1128/IAI.69.3.1488-1491.2001

M3 - Article

C2 - 11179317

AN - SCOPUS:0035119494

VL - 69

SP - 1488

EP - 1491

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 3

ER -